Search Result

Results for "

c-met

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Met/HGFR (166) ADC Antibody (3) Akt (7) AMPK (1) Anaplastic lymphoma kinase (ALK) (10) Angiotensin Receptor (2) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (3) Apoptosis (50) Autophagy (14) Bacterial (2) Bcl-2 Family (1) c-Kit (8) Carbonic Anhydrase (1) Caspase (1) CDK (1) Checkpoint Kinase (Chk) (1) Cytochrome P450 (1) Discoidin Domain Receptor (2) DNA/RNA Synthesis (2) Drug Intermediate (1) Drug-Linker Conjugates for ADC (2) E3 Ligase Ligand-Linker Conjugates (1) EGFR (14) Endogenous Metabolite (1) Environmental Pollutants (1) ERK (3) Estrogen Receptor/ERR (1) FGFR (1) FLT3 (9) Fluorescent Dye (1) G-quadruplex (1) Glutaminase (3) HDAC (3) HIF/HIF Prolyl-Hydroxylase (2) iGluR (3) Isotope-Labeled Compounds (5) JNK (1) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (1) Microtubule/Tubulin (1) Mitosis (1) MMP (1) mTOR (2) NF-κB (1) P-glycoprotein (1) p38 MAPK (3) PARP (3) PDGFR (5) Phosphatase (1) PI3K (2) Pim (1) Polo-like Kinase (PLK) (1) PROTAC Linkers (2) PROTACs (8) RAD51 (3) Raf (3) Reference Standards (13) RET (4) RIP kinase (1) ROS Kinase (10) Small Interfering RNA (siRNA) (2) Src (2) STAT (3) TAM Receptor (13) Target Protein Ligand-Linker Conjugates (3) Topoisomerase (3) Trk Receptor (2) Tyrosinase (3) VEGFR (29)
By Research Areas:	Cancer (174) Cardiovascular Disease (4) Endocrinology (1) Infection (3) Inflammation/Immunology (3) Metabolic Disease (6) Neurological Disease (9)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

190

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: c-Met/HGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50878

Crizotinib Maximum Cited Publications 86 Publications Verification PF-02341066	Ligands for Target Protein for PROTAC Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase	Cancer
Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and *c-Met* inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-13404

Capmatinib 20+ Cited Publications INC280; INCB28060	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-15959

Savolitinib 5+ Cited Publications Volitinib; HMPL-504; AZD-6094	c-Met/HGFR	Cancer
Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable *c-Met* inhibitor with IC₅₀s of 5 nM and 3 nM for c-Met and p-Met, respectively. Savolitinib (AZD-6094) selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. Antineoplastic activity .

HY-14721

Tepotinib 5+ Cited Publications EMD-1214063	c-Met/HGFR Autophagy	Cancer
Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive *c-Met* inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation and induces autophagy. Tepotinib has antitumor effects .

HY-P99391

Telisotuzumab ABT-700; ABBV-400 Antibody	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-11107

PHA-665752 10+ Cited Publications	c-Met/HGFR Autophagy Apoptosis	Cancer
PHA-665752 is a selective, ATP-competitive, and active-site inhibitor of the catalytic activity of *c-Met* kinase (K_i=4 nM; IC₅₀=9 nM). PHA-665752 exhibits >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases. PHA-665752 induces apoptosis and cell cycle arrest, and exhibits cytoreductive antitumor activity .

HY-50683

JNJ-38877605 5+ Cited Publications	c-Met/HGFR	Metabolic Disease Cancer
JNJ-38877605 is an orally active ATP-competitive inhibitor of *c-Met* with an IC₅₀ of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases . JNJ-38877605 inhibits c-Met phosphorylation and regulates lipid accumulation. JNJ-38877605 can be used for tumor and metabolic disease reseach .

HY-50686

Tivantinib 5+ Cited Publications ARQ 197; (3R,4R)-ARQ 198	c-Met/HGFR Apoptosis	Cancer
Tivantinib is a highly selective *c-Met* tyrosine kinase inhibitor with a K_i of 355 nM.

HY-13404C

Capmatinib dihydrochloride hydrate 20+ Cited Publications INC280 dihydrochloride hydrate; INCB-28060 dihydrochloride hydrate	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-13068

Golvatinib 4 Publications Verification E-7050	c-Met/HGFR VEGFR	Cancer
Golvatinib (E-7050) is a potent dual inhibitor of both *c-Met* and VEGFR2 kinases with IC₅₀s of 14 and 16 nM, respectively.

HY-15735

c-Met inhibitor 1 1 Publications Verification	c-Met/HGFR	Cancer
c-Met inhibitor 1 is an orally active *c-Met* inhibitor. c-Met inhibitor 1 can inhibit *c-Met* phosphorylation with an IC₅₀ of 0.010 μM. c-Met inhibitor 1 has antitumor activity and can be used for the research of tumors such as gastric cancer, pancreatic cancer and malignant glioma .

HY-18711A

SCR-1481B1 metatinib anhydrous; c-met inhibitor 2	c-Met/HGFR VEGFR	Cancer
SCR-1481B1 (Metatinib anhydrous) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.

HY-116000

Glumetinib 2 Publications Verification Gumarontinib; SCC244	c-Met/HGFR	Cancer
Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive *c-Met* inhibitor with an IC₅₀ of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity .

HY-15240

c-Kit-IN-1 1 Publications Verification	c-Kit c-Met/HGFR	Cancer
c-Kit-IN-1 is a potent inhibitor of c-Kit and *c-Met* with IC₅₀s of <200 nM.

HY-100946

CEP-40783 2 Publications Verification RXDX-106	TAM Receptor c-Met/HGFR	Cancer
CEP-40783 is a potent, selective and orally available inhibitor of AXL and *c-Met* with IC₅₀ values of 7 nM and 12 nM, respectively.

HY-137455

Terevalefim ANG-3777	c-Met/HGFR	Inflammation/Immunology
Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor .

HY-12017

PF-04217903 2 Publications Verification	c-Met/HGFR	Cancer
PF-04217903 is a potent ATP-competitive c-Met kinase inhibitor with K_i of 4.8 nM for human c-Met. PF-04217903 shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .

HY-14723

AMG-458	c-Met/HGFR	Cancer
AMG-458 is a potent, selective and orally bioavailable *c-Met* inhibitor, with K_i values of 1.2 nM and 2.0 nM for human and mouse c-Met, respectively .

HY-168135

*PROTAC c-Met* degrader-1**	PROTACs c-Met/HGFR	Cancer
PROTAC c-Met degrader-1 is a selective and orally active c-Met PROTAC degrader with a DC₅₀ of 6.21 nM against c-Met. PROTAC c-Met degrader-1 induces CRBN-dependent ubiquitination and proteasomal degradation of c-Met. PROTAC c-Met degrader-1 induces G0/G1 phase arrest in c-Met-dependent cancer cells. PROTAC c-Met degrader-1 kills c-Met-dependent cancer cells. PROTAC c-Met degrader-1 inhibits tumor growth in animal models. PROTAC c-Met degrader-1 can be used for the research of gastric cancer .

HY-13404A

Capmatinib dihydrochloride 20+ Cited Publications INC280 dihydrochloride; INCB28060 dihydrochloride	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-13404B

Capmatinib hydrochloride 20+ Cited Publications INC280 hydrochloride; INCB-28060 hydrochloride	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) hydrochloride is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib hydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib hydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib hydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-P99196

Ficlatuzumab	c-Met/HGFR	Cancer
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the *HGF/c-Met* signaling pathway, and inhibits *c-Met* receptor-mediated cancer cell proliferation, migration, and invasion .

HY-12035

AMG-208 1 Publications Verification	c-Met/HGFR Cytochrome P450	Cancer
AMG-208 is an orally active *c-Met/RON* dual selective inhibitor with an IC₅₀ of 9 nM for c-Met. AMG-208 is a CYP3A4 inhibitor with an IC₅₀ of 32 μM. AMG-208 has anti-cancer activity .

HY-50703

MK-2461 1 Publications Verification	c-Met/HGFR	Cancer
MK-2461 is an ATP-competitive, selective and orally active wild-type and mutant *c-Met* inhibitor (IC₅₀s: 0.4-2.5 nM). MK-2461 also inhibits Ron (IC₅₀ of 7 nM) and Flt1 (IC₅₀ of 10 nM), MK-2461 shows selective for c-MET over other kinases (lC₅₀s = 22-7800 nM). MK-2461 can be used for the study of cancer, such as gastric cancer .

HY-147259

Dalmelitinib	c-Met/HGFR	Cancer
Dalmelitinib is an orally active selective *c-Met* kinase inhibitor (IC₅₀: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) .

HY-14721R

Tepotinib (Standard) EMD-1214063 (Standard)	Reference Standards c-Met/HGFR Autophagy	Cancer
Tepotinib (Standard) is the analytical standard of Tepotinib. This product is intended for research and analytical applications. Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive *c-Met* inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation. Tepotinib has antitumor effects .

HY-124761

Poloppin	Polo-like Kinase (PLK) Autophagy Mitosis	Cancer
Poloppin is a potent, cell penetrant inhibitor of the mitotic Polo-like kinase (PLK) (IC₅₀=26.9 μM) and prevents the protein-protein interaction via the Polo-box domain (PBD) (K_d= 29.5 μM). Poloppin selectively kills cells expressing mutant KRAS, enhancing death in mitosis. Poloppin is used for the study of KRAS-mutant cancers as single agents, or in combination with c-MET inhibitors .

HY-175321

*PROTAC c-Met* degrader-6**	PROTACs c-Met/HGFR Apoptosis	Cancer
PROTAC c-Met degrader-6 is a potent and orally active c-Met PROTACdegrader. PROTAC c-Met degrader-6 significantly induces the degradation of the c-Met protein with DC₅₀s of 0.52 nM and 0.45 nM in EBC-1 and Hs746T. PROTAC c-Met degrader-6 almost abrogates the migratory and invasion abilities of tumor cells and significantly induces the apoptosis and blocks the cell cycle in the G0/G1 phase. PROTAC c-Met degrader-6 can be used for the study of various cancers such as non-small cell lung cancer and stomach cancer (Pink: c-Met ligand (HY-W425461); Blue: E3 ligand (HY-14658); Black: Linker (HY-20797)) .

HY-14721A

Tepotinib hydrochloride EMD-1214063 hydrochloride	c-Met/HGFR Autophagy	Cancer
Tepotinib (EMD-1214063) hydrochloride is an orally active and highly selective, reversible, ATP-competitive *c-Met* inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib hydrochloride inhibits c-Met phosphorylation and induces autophagy. Tepotinib hydrochloride has antitumor effects .

HY-175333

c-Met ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates c-Met/HGFR	Cancer
c-Met ligand-Linker Conjugate 1 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for *c-Met* (HY-W425461) and a PROTAC linker (HY-151862), which recruits E3 ligases. c-Met ligand-Linker Conjugate 1 can be used for synthesis of PROTAC c-Met degrader-5 (HY-175320) .

HY-175320

*PROTAC c-Met* degrader-5**	PROTACs c-Met/HGFR Apoptosis STAT	Cancer
PROTAC c-Met degrader-5 (Compound D19) is an orally active *c-Met* PROTAC degrader with DC₅₀s of 0.42 and 0.32 nM in EBC-1 and Hs746T cells, respectively. PROTAC c-Met degrader-5 significantly induces cell apoptosis, G1 cell cycle arrest, and inhibits cell migration and invasion. PROTAC c-Met degrader-5 has potent antiproliferative and degradation efficacy against c-Met-addicted cancer cells and Tepotinib (HY-14721)-resistant cancer cells . Pink: c-Met ligand (HY-W425461); Blue: CRBN ligase ligand (HY-14658); Black: linker

HY-18711

SCR-1481B1 free base metatinib free base; c-met inhibitor 2 free base	c-Met/HGFR VEGFR	Cancer
SCR-1481B1 free base, also known as Metatinib free base, is a small molecule receptor kinase inhibitor that targets both c-MET and vascular endothelial growth factor receptor 2 (VEGFR2) .

HY-168910

*PROTAC c-Met* degrader-3**	PROTACs c-Met/HGFR	Cancer
PROTAC c-Met degrader-3 (Compound 22b) is a *c-Met* PROTAC degrader. PROTAC c-Met degrader-3 promotes ubiquitination and degradation of c-Met (DC₅₀ of 0.59 nM in EBC-1 cells). PROTAC c-Met degrader-3 can be used for the research of lung cancer (Pink: c-Met ligand (HY-14721); Blue: E3 ligase CRBN ligand (HY-W249500); linker + E3 ligase ligand (HY-168911)) .

HY-170335

*PROTAC c-Met* degrader-2**	PROTACs c-Met/HGFR	Others
PROTAC c-Met degrader-2 (PROTAC2) is a PROTAC-based *c-Met* degrader, with a DC₅₀ of 50 nM (Pink: Foretinib (HY-10338); Black: linker (HY-45124); Blue: CRBN ligand Thalidomide-4-O-C2-NH2 (HY-136162A)) .

HY-133083

BAY-474 1 Publications Verification	c-Met/HGFR	Cancer
BAY-474 is a tyrosine-protein kinase *c-Met* inhibitor. BAY-474 acts as an epigenetics probe .

HY-18307

SYN1143	c-Met/HGFR	Cancer
SYN1143 is a potent, selective and orally active dual inhibitor of *c-Met/RON, with IC₅₀s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on Lck, Tie2, Src, and BTK* with IC₅₀s ranging from 160 to 710 nM. SYN1143 can be used for the research of cancers that RON and c-Met are activated .

HY-174387

KIN-8741	c-Met/HGFR	Cancer
KIN-8741 is a highly selective Type IIb c-Met inhibitor. KIN-8741 has broad activity against c-Met kinase mutations. KIN-8741 shows antitumor activity in MET gene amplified and exon 14 deleted non-small cell lung cancer models. KIN-8741 can be used in the research of c-Met driven cancers, especially advanced tumors carrying MET exon 14 jump mutations, acquired drug resistance mutations, etc .

HY-162679

c-Met degrader-1	c-Met/HGFR Apoptosis	Cancer
c-Met degrader-1 (Compound H11) is an orally active *c-Met* degrader (through the ubiquitin proteasome system). c-Met degrader-1 has anti-hepatocellular carcinoma activity (HCC) and inhibits tumor growth in MHCC97H xenografts. c-Met degrader-1 inhibits HCC cell growth, arrests cell cycle, and induces apoptosis. c-Met degrader-1 may overcome resistance to type Ib inhibitors .

HY-161141

*EGFR/c-Met-IN-2*	c-Met/HGFR	Cancer
EGFR/ C-Met-in-2 (Compound H-22) is a dual inhibitor of *EGFR/c-Met. EGFR/c-Met-IN-2 inhibits cell proliferation by arresting G2/M phase. EGFR/c-Met*-IN-2 has antitumor activity .

HY-175337

c-Met ligand-Linker Conjugate 2	Target Protein Ligand-Linker Conjugates c-Met/HGFR	Cancer
c-Met ligand-Linker Conjugate 2 is a synthesized target protein ligand-linker conjugate that can be used for synthesis of PROTACs, such as PROTAC c-Met degrader-6 (HY-175321). PROTAC c-Met degrader-6 is a c-Met PROTAC degrader with anti-tumor activity ^{[1] ^.}

HY-P991565

CE-355621	c-Met/HGFR	Cancer
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (K_D = 200 pM, IC₅₀ = 466 pM) in A549 cells and cyno c-Met (K_D = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .

HY-149880

c-Met-IN-18	c-Met/HGFR	Cancer
c-Met-IN-18 is ATP competitive type-III c-MET inhibitor of WT and D1228V mutant c-MET. c-Met-IN-18 has inhibitory for WT/D1228V with an IC₅₀ value of 0.013/0.20 ^e.c-Met-IN-18 can be used for the research of c-MET driven cancers . c-Met-IN-18 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-144394

Antitumor agent-45	Apoptosis c-Met/HGFR	Cancer
Antitumor agent-45 (Compound 21) could induce and stimulate A549 cells apoptosis in G0/G1 and G2/M phase. Antitumor agent-45 (Compound 21) inhibits c-Met expression to regulate the growth of tumor cells .

HY-177134

Taligantinib	VEGFR c-Met/HGFR	Cancer
Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma .

HY-150582

c-Met-IN-14	c-Met/HGFR c-Kit FLT3 Apoptosis	Cancer
c-Met-IN-14 (compound 26af) is a selective inhibitor of *c-Met* kinase from N-sulfonylamidine-based derivatives, with an IC₅₀ value of 2.89 nM. c-Met-IN-14 shows anticancer activity by blocking phosphorylation of c-Met, and arrests cell cycle at G2/M phase. c-Met-IN-14 induces apoptosis of A549 cells in a dose-dependent manner .

HY-115937

c-Met-IN-9	c-Met/HGFR Apoptosis	Cancer
c-Met-IN-9, a 4-phenoxypyridine derivative, is a c-Met kinas inhibitor with an IC₅₀ of 12 nM. c-Met-IN-9 induces cells apoptosis, and has antitumor activities .

HY-12017A

PF-04217903 mesylate 2 Publications Verification	c-Met/HGFR	Cancer
PF-04217903 mesylate is a potent ATP-competitive c-Met kinase inhibitor with K_i of 4.8 nM for human c-Met. PF-04217903 mesylate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .

HY-157302

c-Met-IN-21	c-Met/HGFR	Cancer
c-Met-IN-21 (compound 54) is a *c-met* inhibitor with an IC₅₀ value of 0.45? nM, and shows anti-tumor efficacy in vivo .

HY-P99391A

Telisotuzumab (powder) ABT-700 (powder)	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-13404R

Capmatinib (Standard) INC280 (Standard); INCB28060 (Standard)	Reference Standards c-Met/HGFR Apoptosis	Cancer
Capmatinib (Standard) is the analytical standard of Capmatinib. This product is intended for research and analytical applications. Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W015309

Decanoic acid 4 Publications Verification	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Biological Pesticide Research Source Classification Agricultural Research	Environmental Pollutants Endogenous Metabolite iGluR Glutaminase c-Met/HGFR Tyrosinase
Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of *c-Met* and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-N6797

Meleagrin	Infection Alkaloids Microorganisms Classification of Application Fields Disease Research Fields Indole Alkaloids Source Classification	Bacterial c-Met/HGFR Antibiotic
Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of FabI inhibitor. Meleagrin is a lead *c-Met* inhibitory entity useful for the control of c-Met-dependent metastatic and invasive breast malignancies .

HY-W015309R

Decanoic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards iGluR Tyrosinase c-Met/HGFR Glutaminase
Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

Cat. No.	Product Name	Chemical Structure

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-50878S

Crizotinib-d5

Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-W266188

Decanoic acid-13C

Decanoic acid- ¹³C is the ¹³C-labeled Decanoic acid (HY-W015309). Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-50878AS

Crizotinib-d9 hydrochloride

Crizotinib-d₉ hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition .

HY-50878S2

Crizotinib-d9

Crizotinib-d₉ (PF-02341066-d₉) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-50878S1

Crizotinib-d8

Crizotinib-d₈ (PF-02341066-d₈) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-W706452

Cabozantinib-d4 S-malate
Cabozantinib-d₄ (S-malate) (XL184-d₄ (S-malate); BMS-907351-d₄ (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks